Abstract:

Therapeutic Drug Monitoring (TDM) may offer opportunities for optimal allocation of financial resources. Pharmacoeconomics has been increasingly applied to TDM in response to the growing concern of physicians, healthcare decision-makers and the public about rising medical costs. Results from cost-effectiveness analyses (CEA) or cost-utility analyses (CUA) would provide answers in the context of biologic therapies for immune-mediated inflammatory diseases (IMIDs). This webinar will provide an introductory overview of pharmacoeconomics to raise awareness of the importance of cost-effectiveness in the treatment of IMIDs and how to interpret the results of such analyses. Some practical examples of published cost-effectiveness studies in TDM will also be presented.

Pawel Kawalec is the Head of the Nutrition and Drug Research Department of the Institute of Public Health, Jagiellonian University Medical College (JU MC). Graduate from the Faculty of Medicine of the JU MC (2000); public health specialist; since 2002, he has been employed at the Institute of Public Health JU MC. He conducts research and teaching in areas such as: pharmacoeconomics, Health Technology Assessment, Evidence-Based Medicine, drug management, pharmacology. He was a leader of numerous national and international scientific projects, and co-author of over a hundred Impact Factor publications. His research focuses on meta-analysis and network meta-analysis for evaluation of clinical effectiveness and safety profile of biologic therapies in inflammatory bowel diseases but also on reimbursement issues and availability of innovative drugs for patients within the EU.